← Back to Search

Ibrutinib for Lymphoma

Phase 2
Waitlist Available
Led By Barbara Pro, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing a drug to see if it can help maintain remission for patients with mantle cell lymphoma who have responded to chemotherapy.

Who is the study for?
This trial is for patients with mantle cell lymphoma who've responded to induction chemotherapy. They must have finished chemo at least 14 days ago but no more than 90 days prior, or show engraftment post-auto stem cell transplant. Participants need an ECOG performance status of <=2, indicating they can perform daily activities with some limitations.
What is being tested?
The study tests if the drug Ibrutinib is effective as a maintenance therapy after initial chemo in MCL patients. It involves taking Ibrutinib and monitoring its effects on the disease through lab biomarker analysis to see how well it helps control cancer growth.
What are the potential side effects?
Ibrutinib may cause side effects like diarrhea, bleeding problems, high blood pressure, infections due to low white blood cells count, fatigue, and muscle and bone pain. The severity of these side effects can vary from person to person.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine the Progression-free Survival (PFS) Rate After 3 Years
Secondary study objectives
Incidence of Adverse Events, Defined According to the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.0
Overall Survival (OS) After 4 Years
Rate of Conversion From Partial Response (PR) to Complete Response (CR)
Other study objectives
Compare Minimum Residual Disease (MRD) Results Overtime by Polymerase Chain Reaction (PCR) and Correlate These With PFS and OS

Side effects data

From 2018 Phase 3 trial • 391 Patients • NCT01578707
34%
Infusion Related Reaction
30%
Fatigue
23%
Cough
20%
Nausea
17%
Anaemia
17%
Diarrhoea
14%
Pyrexia
14%
Peripheral Sensory Neuropathy
13%
Neutropenia
12%
Thrombocytopenia
12%
Night Sweats
10%
Constipation
10%
Abdominal Pain
9%
Upper Respiratory Tract Infection
9%
Dyspnoea
9%
Pruritus
8%
Insomnia
8%
Oedema Peripheral
8%
Decreased Appetite
8%
Muscle Spasms
7%
Arthralgia
7%
Back Pain
6%
Pneumonia
6%
Vomiting
6%
Sinusitis
6%
Weight Decreased
6%
Headache
5%
Anxiety
5%
Dry Eye
5%
Pain in Extremity
5%
Musculoskeletal Pain
5%
Oropharyngeal pain
5%
Rash Erythematous
5%
Urinary Tract Infection
5%
Dizziness
5%
Paraesthesia
4%
Asthenia
4%
Nasopharyngitis
4%
Myalgia
4%
Rash Maculo-Papular
4%
Rash
3%
Lacrimation Increased
3%
Lymphocytosis
3%
Vision Blurred
3%
Eye Pain
3%
Stomatitis
3%
Dyspepsia
3%
Chills
3%
Influenza Like Illness
3%
Contusion
3%
Hypokalaemia
3%
Hyperglycaemia
3%
Epistaxis
3%
Rhinorrhoea
3%
Nasal Congestion
3%
Productive Cough
3%
Skin Lesion
3%
Actinic Keratosis
2%
Depression
2%
Confusional State
2%
Pollakiuria
2%
Febrile Neutropenia
2%
Chronic Lymphocytic Leukaemia
2%
Increased Tendency to Bruise
2%
Eye Irritation
2%
Photophobia
2%
Vitreous Floaters
2%
Gastrooesophageal Reflux Disease
2%
Abdominal Pain Upper
2%
Haemorrhoids
2%
Cellulitis
2%
Herpes Zoster
2%
Hyperuricaemia
2%
Hyponatraemia
2%
Bone Pain
2%
Muscular Weakness
2%
Dyspnoea Exertional
2%
Dry Skin
2%
Hypertension
1%
Cataract
1%
Haematuria
1%
Spinal Compression Fracture
1%
Autoimmune Haemolytic Anaemia
1%
Acute myocardial infarction
1%
Sinus Tachycardia
1%
Haemolytic Anaemia
1%
Myocardial infarction
1%
Methaemoglobinaemia
1%
Cardiac Failure
1%
Atrial Fibrillation
1%
Supraventricular Tachycardia
1%
Malabsorption
1%
Sepsis
1%
Bacteraemia
1%
Lower Respiratory Tract Infection
1%
Infection
1%
Bronchitis
1%
Pneumocystis Jirovecii Ppneumonia
1%
Influenza
1%
Neutropenic Sepsis
1%
Pneumonia Pseudomonal
1%
Folliculitis
1%
Pseudomonas Infection
1%
Respiratory Tract Infection
1%
Pneumonia Bacterial
1%
Febrile Infection
1%
Abscess Limb
1%
Anal Infection
1%
Breast Cellulitis
1%
Herpes Simplex
1%
Infectious Pleural Effusion
1%
Sepsis Syndrome
1%
Stenotrophomonas Infection
1%
Multiple Fractures
1%
Muscle Strain
1%
Tumour Lysis Syndrome
1%
Squamous Cell Carcinoma
1%
Metastatic Squamous Cell Carcinoma
1%
Major Depression
1%
Acute Kidney Injury
1%
Renal Failure
1%
Renal Impairment
1%
Haemoptysis
1%
Pneumonitis
1%
Pulmonary Embolism
1%
Pulmonary Mass
1%
Respiratory Tract Inflammation
1%
Deep Vein Thrombosis
1%
Visual Acuity Reduced
1%
Flatulence
1%
Malaise
1%
Conjunctivitis
1%
Ear Infection
1%
Fall
1%
Basal Cell Carcinoma
1%
Petechiae
1%
Blood Blister
1%
Septic Shock
1%
Effusion
1%
Anaphylactic Shock
1%
Lung Infection Pseudomonal
1%
Nocardiosis
1%
Ophthalmic Herpes Zoster
1%
Pneumonia Mycoplasmal
1%
Tumour Pain
1%
Dry Mouth
1%
Dysuria
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ofatumumab (Arm A)
Ibrutinib (Arm B)

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (ibrutinib)Experimental Treatment2 Interventions
Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tyrosine
FDA approved

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,645 Previous Clinical Trials
958,557 Total Patients Enrolled
Janssen Scientific Affairs, LLCIndustry Sponsor
164 Previous Clinical Trials
579,936 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,925 Previous Clinical Trials
41,017,964 Total Patients Enrolled
~3 spots leftby Nov 2025